WO2008157791A2 - Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones - Google Patents

Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones Download PDF

Info

Publication number
WO2008157791A2
WO2008157791A2 PCT/US2008/067742 US2008067742W WO2008157791A2 WO 2008157791 A2 WO2008157791 A2 WO 2008157791A2 US 2008067742 W US2008067742 W US 2008067742W WO 2008157791 A2 WO2008157791 A2 WO 2008157791A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
compound
usldocs
agents
compounds
Prior art date
Application number
PCT/US2008/067742
Other languages
English (en)
French (fr)
Other versions
WO2008157791A3 (en
Inventor
Judith Kelleher Anderson
Original Assignee
Neuronascent, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP08771642.9A priority Critical patent/EP2170340B1/en
Priority to AU2008265600A priority patent/AU2008265600B2/en
Priority to RU2010100945/15A priority patent/RU2521333C2/ru
Priority to DK08771642.9T priority patent/DK2170340T3/en
Priority to PL08771642T priority patent/PL2170340T3/pl
Priority to US12/664,995 priority patent/US8609840B2/en
Priority to CA2693062A priority patent/CA2693062C/en
Priority to JP2010513461A priority patent/JP2010530898A/ja
Application filed by Neuronascent, Inc. filed Critical Neuronascent, Inc.
Priority to KR1020157008401A priority patent/KR101600054B1/ko
Priority to CN200880021069A priority patent/CN101842100A/zh
Priority to ES08771642.9T priority patent/ES2564826T3/es
Publication of WO2008157791A2 publication Critical patent/WO2008157791A2/en
Priority to IL202485A priority patent/IL202485A/en
Publication of WO2008157791A3 publication Critical patent/WO2008157791A3/en
Priority to US14/079,489 priority patent/US9096613B2/en
Priority to US14/751,403 priority patent/US9592234B2/en
Priority to IL251169A priority patent/IL251169A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PCT/US2008/067742 2007-06-21 2008-06-20 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones WO2008157791A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
KR1020157008401A KR101600054B1 (ko) 2007-06-21 2008-06-20 이소티아졸로피리미디논을 사용하는 신경 발생을 자극하고 신경 변성을 억제하는 방법 및 조성물
AU2008265600A AU2008265600B2 (en) 2007-06-21 2008-06-20 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
CN200880021069A CN101842100A (zh) 2007-06-21 2008-06-20 使用异噻唑并嘧啶酮刺激神经发生和抑制神经元变性的方法和组合物
PL08771642T PL2170340T3 (pl) 2007-06-21 2008-06-20 Sposoby i kompozycje stymulacji neurogenezy i hamowania degeneracji neuronów z wykorzystaniem izotiazolopirymidonów
US12/664,995 US8609840B2 (en) 2007-06-21 2008-06-20 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
CA2693062A CA2693062C (en) 2007-06-21 2008-06-20 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
JP2010513461A JP2010530898A (ja) 2007-06-21 2008-06-20 イソチアゾロピリミジノンを用いた神経形成を刺激するためおよびニューロン変性を阻害するための方法および組成物
EP08771642.9A EP2170340B1 (en) 2007-06-21 2008-06-20 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
RU2010100945/15A RU2521333C2 (ru) 2007-06-21 2008-06-20 Способы и композиции для стимулирования нейрогенеза и ингибирования дегенерации нейронов с использованием изотиазолопиримидинонов
DK08771642.9T DK2170340T3 (en) 2007-06-21 2008-06-20 Methods and compositions for Stimulating neurogenesis and inhibition of neuronal degeneration BY USING ISOTHIAZOLOPYRIMIDINONER
ES08771642.9T ES2564826T3 (es) 2007-06-21 2008-06-20 Métodos y composiciones para estimular neurogénesis e inhibir degeneración neuronal utilizando isotiazolopirimidinonas
IL202485A IL202485A (en) 2007-06-21 2009-12-03 Methods and preparations for stimulating nerve cell formation and inhibiting neuronal degeneration through the use of isolopyrimidinone isotopes
US14/079,489 US9096613B2 (en) 2007-06-21 2013-11-13 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
US14/751,403 US9592234B2 (en) 2007-06-21 2015-06-26 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
IL251169A IL251169A0 (en) 2007-06-21 2017-03-14 Methods and preparations for stimulating the generation of nerve cells and inhibiting the degeneration of nerve cells through the use of isothiazolopyrimidinones

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94552407P 2007-06-21 2007-06-21
US60/945,524 2007-06-21

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/664,995 A-371-Of-International US8609840B2 (en) 2007-06-21 2008-06-20 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
US14/079,489 Division US9096613B2 (en) 2007-06-21 2013-11-13 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones

Publications (2)

Publication Number Publication Date
WO2008157791A2 true WO2008157791A2 (en) 2008-12-24
WO2008157791A3 WO2008157791A3 (en) 2009-12-30

Family

ID=40156978

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/067742 WO2008157791A2 (en) 2007-06-21 2008-06-20 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones

Country Status (13)

Country Link
US (3) US8609840B2 (US20100298318A1-20101125-C00002.png)
EP (2) EP2170340B1 (US20100298318A1-20101125-C00002.png)
JP (4) JP2010530898A (US20100298318A1-20101125-C00002.png)
KR (2) KR101565971B1 (US20100298318A1-20101125-C00002.png)
CN (1) CN101842100A (US20100298318A1-20101125-C00002.png)
AU (1) AU2008265600B2 (US20100298318A1-20101125-C00002.png)
CA (1) CA2693062C (US20100298318A1-20101125-C00002.png)
DK (1) DK2170340T3 (US20100298318A1-20101125-C00002.png)
ES (1) ES2564826T3 (US20100298318A1-20101125-C00002.png)
IL (2) IL202485A (US20100298318A1-20101125-C00002.png)
PL (1) PL2170340T3 (US20100298318A1-20101125-C00002.png)
RU (1) RU2521333C2 (US20100298318A1-20101125-C00002.png)
WO (1) WO2008157791A2 (US20100298318A1-20101125-C00002.png)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014152013A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
CN105287582A (zh) * 2009-09-22 2016-02-03 诺伊罗纳森特公司 用于治疗唐氏综合征的方法和药物组合物
US9284297B2 (en) 2008-08-11 2016-03-15 President And Fellows Of Harvard College Halofuginone analogs for inhibition of tRNA synthetases and uses thereof
US9777010B2 (en) 2014-04-30 2017-10-03 The Trustees Of Columbia University In The City Of New York Substituted 4-phenylpiperidines, their preparation and use
US9926271B2 (en) 2013-03-14 2018-03-27 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
US10155742B2 (en) 2012-01-13 2018-12-18 President And Fellows Of Harvard College Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions
US11708353B2 (en) 2018-06-08 2023-07-25 The General Hospital Corporation Inhibitors of prolyl-tRNA-synthetase

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2170340B1 (en) * 2007-06-21 2016-02-24 Neuronascent, INC. Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
RU2613765C1 (ru) * 2016-01-26 2017-03-21 Федеральное государственное автономное образовательное учреждение высшего образования "Северо-Восточный федеральный университет им. М.К.Аммосова" Способ лечения спиноцеребеллярной атаксии
US10064833B2 (en) * 2016-08-04 2018-09-04 Syneurx International (Taiwan) Corp. Compositions containing benzoate compound and tannic acid for treating central nervous system disorders
RU2670128C2 (ru) * 2016-12-16 2018-10-18 Федеральное государственное автономное образовательное учреждение высшего образования "Балтийский федеральный университет имени Иммануила Канта" (БФУ им. И. Канта) Способ генетической регистрации и коррекции нейрогенеза на основе генетических конструкций для трансфекции нейронов
RU2675111C2 (ru) * 2017-03-31 2018-12-17 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фундаментальной и клинической иммунологии" Способ стимуляции нейрогенеза в гиппокампе
BR112020000085A2 (pt) * 2017-07-03 2020-07-07 Bayer Cropscience Aktiengesellschaft novos biciclos baseados em isotiazol, processos para sua preparação e seu uso como herbicidas e/ou reguladores de crescimento da planta.

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CH588887A5 (US20100298318A1-20101125-C00002.png) 1974-07-19 1977-06-15 Battelle Memorial Institute
US4089809A (en) * 1976-03-01 1978-05-16 The United States Of America As Represented By The United States Department Of Energy Regenerable sorbent and method for removing hydrogen sulfide from hot gaseous mixtures
US4233871A (en) * 1978-04-26 1980-11-18 Alessi Anthony A Notching tool
EP0032578B1 (de) * 1980-01-16 1984-07-25 Hans Georg Prof. Dr. Weder Verfahren und Dialysiereinrichtung zur Herstellung von Bilayer-Vesikeln und Verwendung der Bilayer-Vesikel
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4438253A (en) * 1982-11-12 1984-03-20 American Cyanamid Company Poly(glycolic acid)/poly(alkylene glycol) block copolymers and method of manufacturing the same
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4532089A (en) * 1984-01-14 1985-07-30 Northwestern University Method of preparing giant size liposomes
US4897269A (en) 1984-09-24 1990-01-30 Mezei Associates Limited Administration of drugs with multiphase liposomal delivery system
JP2670680B2 (ja) 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5820880A (en) 1995-06-07 1998-10-13 The United States Of America As Represented By The Secretary Of The Army Liposomal formulation
US5665428A (en) 1995-10-25 1997-09-09 Macromed, Inc. Preparation of peptide containing biodegradable microspheres by melt process
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6287588B1 (en) 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
MXPA01011429A (es) 1999-05-11 2003-09-10 Ortho Mcneil Pharm Inc Modelado farmacocinetico y farmacodinamico de administracion de eritropoyetina.
KR20050107784A (ko) 2003-03-07 2005-11-15 아스트라제네카 아베 신규한 융합 복소환 및 이의 용도
EP1475094B8 (en) 2003-05-06 2011-01-12 Ustav Experimentalni Botaniky AV CR, v.v.i. (Institute of Experimental Botany Academy of Sciences of the Czech Republic, PRO) Pyrazolo[4,3-D]pyrimidines, process for their preparation and methods of use
US7022850B2 (en) * 2003-05-22 2006-04-04 Bristol-Myers Squibb Co. Bicyclicpyrimidones and their use to treat diseases
US20070249636A1 (en) * 2004-08-18 2007-10-25 Astrazeneca Ab Selected Fused Heterocyclics and Uses Thereof
AU2006287378A1 (en) * 2005-09-07 2007-03-15 Braincells, Inc. Modulation of neurogenesis by HDac inhibition
EP2170340B1 (en) * 2007-06-21 2016-02-24 Neuronascent, INC. Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG ET AL., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 17, 2007, pages 4303 - 4307

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9284297B2 (en) 2008-08-11 2016-03-15 President And Fellows Of Harvard College Halofuginone analogs for inhibition of tRNA synthetases and uses thereof
CN105287582A (zh) * 2009-09-22 2016-02-03 诺伊罗纳森特公司 用于治疗唐氏综合征的方法和药物组合物
US10155742B2 (en) 2012-01-13 2018-12-18 President And Fellows Of Harvard College Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions
US10570148B2 (en) 2013-03-14 2020-02-25 The Trustees Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
EP3495357A1 (en) * 2013-03-14 2019-06-12 The Trustees of Columbia University in the City of New York 4-phenylpiperidines, their preparation and use
US11919913B2 (en) 2013-03-14 2024-03-05 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
US9926271B2 (en) 2013-03-14 2018-03-27 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
US11028098B2 (en) 2013-03-14 2021-06-08 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
EP2968304A1 (en) * 2013-03-14 2016-01-20 The Trustees of Columbia University in the City of New York 4-phenylpiperidines, their preparation and use
US10273243B2 (en) 2013-03-14 2019-04-30 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
EP2968304A4 (en) * 2013-03-14 2016-08-10 Univ Columbia 4-PHENYLPIPERIDINES, PREPARATION THEREOF AND USE THEREOF
US10787453B2 (en) 2013-03-14 2020-09-29 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
US10421720B2 (en) 2013-03-14 2019-09-24 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
WO2014152013A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
US10407433B2 (en) 2014-04-30 2019-09-10 The Trustees Of Columbia University In The City Of New York Substituted 4-phenylpiperidines, their preparation and use
US10913746B2 (en) 2014-04-30 2021-02-09 The Trustees Of Columbia University In The City Of New York Substituted 4-phenylpiperidines, their preparation and use
US10072016B2 (en) 2014-04-30 2018-09-11 The Trustees Of Columbia University In The City Of New York Substituted 4-phenylpiperidines, their preparation and use
US11649240B2 (en) 2014-04-30 2023-05-16 The Trustees Of Columbia University In The City Of New York Substituted 4-phenylpiperidines, their preparation and use
US9777010B2 (en) 2014-04-30 2017-10-03 The Trustees Of Columbia University In The City Of New York Substituted 4-phenylpiperidines, their preparation and use
US11708353B2 (en) 2018-06-08 2023-07-25 The General Hospital Corporation Inhibitors of prolyl-tRNA-synthetase

Also Published As

Publication number Publication date
RU2521333C2 (ru) 2014-06-27
US20140171428A1 (en) 2014-06-19
AU2008265600B2 (en) 2013-10-31
CN101842100A (zh) 2010-09-22
JP2017066166A (ja) 2017-04-06
IL202485A0 (en) 2010-06-30
KR101565971B1 (ko) 2015-11-05
PL2170340T3 (pl) 2016-06-30
JP2014196308A (ja) 2014-10-16
US9096613B2 (en) 2015-08-04
WO2008157791A3 (en) 2009-12-30
US8609840B2 (en) 2013-12-17
AU2008265600A1 (en) 2008-12-24
ES2564826T3 (es) 2016-03-29
RU2010100945A (ru) 2011-07-27
JP6081528B2 (ja) 2017-02-15
EP2170340B1 (en) 2016-02-24
EP2170340A4 (en) 2010-12-08
IL202485A (en) 2017-03-30
CA2693062A1 (en) 2008-12-24
EP3053584A1 (en) 2016-08-10
US9592234B2 (en) 2017-03-14
DK2170340T3 (en) 2016-03-14
IL251169A0 (en) 2017-04-30
JP2010530898A (ja) 2010-09-16
US20160022682A1 (en) 2016-01-28
EP2170340A2 (en) 2010-04-07
KR20150041668A (ko) 2015-04-16
CA2693062C (en) 2016-08-09
US20100298318A1 (en) 2010-11-25
JP2015163648A (ja) 2015-09-10
KR101600054B1 (ko) 2016-03-04
JP5850981B2 (ja) 2016-02-03
KR20100040728A (ko) 2010-04-20

Similar Documents

Publication Publication Date Title
US9592234B2 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
US9539261B2 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
AU2010298440B2 (en) Methods and pharmaceutical compositions for treating down syndrome
AU2013245563B2 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880021069.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08771642

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2693062

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008265600

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2010513461

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 7462/CHENP/2009

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008265600

Country of ref document: AU

Date of ref document: 20080620

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20107001298

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010100945

Country of ref document: RU

Ref document number: 2008771642

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12664995

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 251169

Country of ref document: IL